-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Cara Therapeutics and Vifor Pharma jointly announced that the US FDA has approved the marketing of Korsuva (difelikefalin) for the treatment of moderate to severe itching in adult patients with chronic kidney disease (CKD) undergoing dialysis
This approval is based on the results of two pivotal Phase 3 clinical trials and supporting data obtained from 32 clinical studies
▲Korsuva reached the primary endpoint in two key Phase 3 clinical trials (Image source: Cara Therapeutics official website)
Korsuva is a "first-in-class" κ opioid receptor (KOR) agonist, which directly inhibits the activity of peripheral neurons that produce itching, so it can be used to relieve itching due to many reasons
▲The mechanism of Korsuva (picture source: Cara Therapeutics official website)
Reference materials:
[1] Cara Therapeutics and Vifor Pharma announce US FDA approval of KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients.
(The original text has been deleted)